Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

June 18, 2024 Osaka, Japan & Cambridge, Mass., United States SKYLINE  was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome (DS).1 Soticlestat…